Addressing Dementia Via Agitation-Centered Evaluation (ADVANCE)

August 22, 2023 updated by: Axsome Therapeutics, Inc.

A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
366

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • Melbourne, Victoria
      • Caulfield, Melbourne, Victoria, Australia, 3162
        • Axsome study site
  • United States
    • Arizona
      • Gilbert, Arizona, United States, 85297
        • Axsome study site
      • Phoenix, Arizona, United States, 85004
        • Axsome study site
      • Scottsdale, Arizona, United States, 85251
        • Axsome study site
      • Scottsdale, Arizona, United States, 85258
        • Axsome study site
      • Tucson, Arizona, United States, 85704
        • Axsome study site
    • Arkansas
      • Little Rock, Arkansas, United States, 72209
        • Axsome study site
    • California
      • Canoga Park, California, United States, 91303
        • Axsome study site
      • Costa Mesa, California, United States, 92626
        • Axsome study site
      • Fresno, California, United States, 93710
        • Axsome study site
      • Long Beach, California, United States, 90806
        • Axsome study site
      • Long Beach, California, United States, 90807
        • Axsome study site
      • Los Alamitos, California, United States, 90720
        • Axsome study site
      • Riverside, California, United States, 92503
        • Axsome study site
      • Sacramento, California, United States, 95821
        • Axsome study site
      • Santa Ana, California, United States, 92705
        • Axsome study site
      • Santa Clarita, California, United States, 91321
        • Axsome study site
      • Sherman Oaks, California, United States, 91403
        • Axsome study site
      • Simi Valley, California, United States, 93065
        • Axsome study site
      • Temecula, California, United States, 92591
        • Axsome study site
      • Ventura, California, United States, 93003
        • Axsome study site
    • Colorado
      • Colorado Springs, Colorado, United States, 80910
        • Axsome study site
    • Connecticut
      • Cromwell, Connecticut, United States, 06416
        • Axsome study site
      • New London, Connecticut, United States, 06320
        • Axsome study site
    • Florida
      • Apopka, Florida, United States, 32703
        • Axsome study site
      • Boca Raton, Florida, United States, 33487
        • Axsome study site
      • Boynton Beach, Florida, United States, 33437
        • Axsome study site
      • Coconut Creek, Florida, United States, 33066
        • Axsome study site
      • Greenacres City, Florida, United States, 33467
        • Axsome study site
      • Hallandale Beach, Florida, United States, 33009
        • Axsome study site
      • Hialeah, Florida, United States, 33012
        • Axsome study site
      • Lake City, Florida, United States, 32055
        • Axsome study site
      • Miami, Florida, United States, 33122
        • Axsome study site
      • Miami, Florida, United States, 33165
        • Axsome study site
      • Orlando, Florida, United States, 32807
        • Axsome study site
      • Pensacola, Florida, United States, 32502
        • Axsome study site
      • Port Orange, Florida, United States, 32127
        • Axsome study site
      • Spring Hill, Florida, United States, 34609
        • Axsome study site
      • Tampa, Florida, United States, 33609
        • Axsome study site
      • Tampa, Florida, United States, 33613
        • Axsome study site
    • Georgia
      • Atlanta, Georgia, United States, 30331
        • Axsome study site
      • Decatur, Georgia, United States, 30030
        • Axsome study site
    • Hawaii
      • Honolulu, Hawaii, United States, 96817
        • Axsome study site
    • Idaho
      • Boise, Idaho, United States, 83704
        • Axsome study site
    • Illinois
      • Flossmoor, Illinois, United States, 60422
        • Axsome study site
    • Indiana
      • Avon, Indiana, United States, 46123
        • Axsome study site
    • Kansas
      • Overland Park, Kansas, United States, 66212
        • Axsome study site
      • Topeka, Kansas, United States, 66606
        • Axsome study site
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70808
        • Axsome study site
      • Lake Charles, Louisiana, United States, 70629
        • Axsome study site
    • Mississippi
      • Hattiesburg, Mississippi, United States, 39401
        • Axsome study site
    • Missouri
      • Chesterfield, Missouri, United States, 63005
        • Axsome study site
      • Saint Louis, Missouri, United States, 63128
        • Axsome study site
    • Nevada
      • Las Vegas, Nevada, United States, 89102
        • Axsome study site
      • Las Vegas, Nevada, United States, 89109
        • Axsome study site
    • New Jersey
      • Princeton, New Jersey, United States, 08540
        • Axsome study site
      • Toms River, New Jersey, United States, 08755
        • Axsome study site
    • New York
      • Albany, New York, United States, 12208
        • Axsome study site
      • Brooklyn, New York, United States, 11229
        • Axsome study site
      • New York, New York, United States, 10036
        • Axsome study site
      • New York, New York, United States, 10128
        • Axsome study site
      • Staten Island, New York, United States, 10312
        • Axsome study site
    • North Carolina
      • Charlotte, North Carolina, United States, 28270
        • Axsome study site
      • Charlotte, North Carolina, United States, 28211
        • Axsome study site
      • Winston-Salem, North Carolina, United States, 27103
        • Axsome study site
    • Ohio
      • Cincinnati, Ohio, United States, 45069
        • Axsome study site
      • Dayton, Ohio, United States, 45459
        • Axsome study site
      • Shaker Heights, Ohio, United States, 44122
        • Axsome study site
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73112
        • Axsome study site
    • Texas
      • DeSoto, Texas, United States, 75115
        • Axsome study site
      • McKinney, Texas, United States, 75071
        • Axsome study site
      • Wichita Falls, Texas, United States, 76309
        • Axsome study site
    • Utah
      • Orem, Utah, United States, 84058
        • Axsome study site
    • Virginia
      • Charlottesville, Virginia, United States, 22903
        • Axsome study site
      • Richmond, Virginia, United States, 23235
        • Axsome study site
    • Washington
      • Bellevue, Washington, United States, 98007
        • Axsome study site
      • Everett, Washington, United States, 98201
        • Axsome study site
      • Spokane, Washington, United States, 99202
        • Axsome study site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

61 years to 86 years (Older Adult)

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  • Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion Criteria:

  • Patient has dementia predominantly of non-Alzheimer's type.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: AXS-05
AXS-05 tablets taken by mouth for 5 weeks.
Drug: AXS-05
AXS-05
Active Comparator: Bupropion
Bupropion tablets taken by mouth for 5 weeks.
Drug: Bupropion
Bupropion
Placebo Comparator: Placebo
Placebo tablets taken by mouth for 5 weeks.
Drug: Placebo
Placebo

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in CMAI Total Score
Time Frame: 5 weeks
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).
5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Axsome Therapeutics, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 13, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 17, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 17, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 20, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 20, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 21, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 13, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 22, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • AXS-05-AD-301

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings